AZYO Aziyo Biologics

Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2025 financial results after market close on Thursday, August 14, 2025. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day.

The conference call can be accessed using the following information:

Webcast:

U.S. Investors: 877-407-8029

International Investors: 201-689-8029

Conference ID: 13754773

Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the “Investors” section of the Elutia website at .

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit .

Investors:

Matt Steinberg

FINN Partners

This press release was published by a CLEAR® Verified individual.



EN
31/07/2025

Underlying

AZYOAziyo Biologics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aziyo Biologics

 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at V...

Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange GAITHERSBURG, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been selected to exhibit the EluPro™ Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange (“Vizient”). ®, the nation’s largest provider-driven healthcare performance improvement company, will hold the Innovative Technology Exchange on Wednesday, September 17, 2025 in Las Veg...

12h / 51m 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Participate in Upcoming Investor Conferences

Elutia to Participate in Upcoming Investor Conferences GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York: Cantor Global Healthcare ConferenceFormat: Fireside Chat and 1x1 MeetingsFireside Chat Date and Time: Thursday, September 4, 2025, 9:45 a.m. ETWebcast Link: H.C. Wainwright 27th Annual Global Inves...

August 27, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adopti...

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the second quarter of 2025. Since full launch in January 2025, EluPro has rapidly established itself as the preferred antibi...

August 14, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Report Second Quarter 2025 Financial Results on Thursday, Au...

Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2025 financial results after market close on Thursday, August 14, 2025. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following informati...

July 31, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medic...

Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medical Device Innovator Award GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Michelle LeRoux Williams, Chief Scientific Officer, has been awarded the Medical Device Innovator Award by the Washington Business Journal. This award recognizes Dr. Williams’ groundbreaking contributions to the medical device industry, particularly her leadership in the development and successful commercializatio...

July 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch